EVOK Insider Trading Activity and SEC Form 4 Filings
EVOK insider trading summary
No open-market insider purchases or sales of Evoke Pharma Inc (EVOK) have been reported on SEC Form 4 in the past 12 months.
Latest EVOK insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Nov 6, 2025 | Roger M. Klein | 10% Owner | Sell | $53K (5,000 @ $10.66) |
| Nov 6, 2025 | Roger M. Klein | 10% Owner | Sell | $43K (4,000 @ $10.65) |
| Jan 28, 2025 | Nantahala Capital Management, LLC | 10% Owner | Sell | $180 (41 @ $4.39) |
| Jan 28, 2025 | Wilmot B. Harkey | 10% Owner | Sell | $180 (41 @ $4.39) |
| Jan 28, 2025 | Daniel Mack | 10% Owner | Sell | $180 (41 @ $4.39) |
| Dec 14, 2020 | David A Gonyer | President and CEO | Sell | $70K (23,954 @ $2.94) |
| Dec 11, 2020 | David A Gonyer | President and CEO | Sell | $139K (48,046 @ $2.90) |
| Dec 11, 2020 | Matthew J D'Onofrio | Exec VP, Chief Bus. Officer | Sell | $117K (40,357 @ $2.91) |
| Dec 10, 2020 | Matthew J D'Onofrio | Exec VP, Chief Bus. Officer | Sell | $17K (5,643 @ $2.95) |
| Aug 20, 2018 | Lvp Gp III, LLC | 10% Owner | Buy | $55K (23,256 @ $2.35) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.